Connor Clark & Lunn Investment Management Ltd. Increases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Connor Clark & Lunn Investment Management Ltd. lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 35.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 302,536 shares of the biopharmaceutical company’s stock after acquiring an additional 79,602 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.10% of Amicus Therapeutics worth $2,850,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in FOLD. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics in the 3rd quarter worth about $55,000. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics in the fourth quarter worth approximately $79,000. Virtu Financial LLC bought a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $107,000. KBC Group NV boosted its holdings in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,120 shares during the period. Finally, Stephens Inc. AR purchased a new position in Amicus Therapeutics during the 4th quarter valued at $101,000.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on FOLD shares. Wells Fargo & Company decreased their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Up 2.5 %

Amicus Therapeutics stock opened at $9.12 on Tuesday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The firm has a market cap of $2.80 billion, a P/E ratio of -50.67, a P/E/G ratio of 1.51 and a beta of 0.69. The business has a fifty day moving average of $9.37 and a two-hundred day moving average of $10.13. Amicus Therapeutics, Inc. has a twelve month low of $8.55 and a twelve month high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.